-
May 16, 2017PREVIEW
Use of once-daily lixisenatide (Adlyxin—Sanofi-Aventis) in older, nonfrail patients whose type 2 diabetes (T2D) was not controlled on their current antidiabetic regimen resulted in improvements in...
-
March 27, 2017PREVIEW
A new position statement by the American Diabetes Association (ADA) focuses on prevention, screening, and management of several diabetic neuropathies, including distal symmetric polyneuropathy (...
-
March 7, 2017PREVIEW
Metformin remains the initial treatment of choice for patients with type 2 diabetes, and if a second agent is needed, clinicians should consider adding a sulfonylurea, a thiazolidinedione, a...
-
December 27, 2016PREVIEW
Intensive glycemic therapy in patients with type 2 diabetes who were also receiving beta blockers was associated with a reduction in the risk of cardiovascular (CV) events compared with those on...
-
August 16, 2016PREVIEW
Addition of liraglutide (Victoza—Novo Nordisk) to standard of care therapy in patients with type 2 diabetes at high risk for cardiovascular (CV) events resulted in a reduced risk of adverse CV...
Pages
